New Formulations of Propafenone to Treat Atrial Fibrillation

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 193 participants.

Also called NCT02710669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 193 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02710669
Other papers using this trial's data
  • A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction Circulation. Arrhythmia and electrophysiology, 2022-10 DOI, PubMed 36166682, PMC9588733 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02710669. Randomized; triple masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2020-03-11 (actual). Results posted on 2021-05-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
New Formulations of Propafenone to Treat Atrial Fibrillation
Intervention (Drug)
(R)-propafenone
Intervention (Drug)
(S)-Propafenone
Intervention (Drug)
Placebo
Lead sponsor
Vanderbilt University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct02710669
Content hash
96f9bcdfa2a51b60ff570c6ae9df6b1f65eccce4ffe0efc1cc5b694f9aa9354a